The participating funds pursue the goal of concluding discount contracts for the active substance infliximab with all suitable pharmaceutical companies in accordance with Section 130a (8) SGB V. The contract is concluded as part of the open house biologics process of the participating funds:

Individual negotiations on the content of the contract are not conducted; uniform conditions apply. The participating health insurers do not guarantee exclusivity for individual contractual partners. The contract runs for a maximum of 24 months starting on 1.4.2020. The contract ends on March 31, 2022, regardless of the date of the conclusion of the contract. All further information can be found in the participation and contract documents.

It is possible to join this open house biological process at any time within the contract period.

A contract is concluded with all pharmaceutical companies that meet the requirements of Annex 4 to the contract (self-declaration for approval and for the company) and confirm this with their signature.

This announcement does not apply to the award of a public contract within the meaning of the Public Procurement Directive (2014/24 / EC) or the antitrust law. In the interest of the broadest possible information for interested pharmaceutical companies, this announcement is made in the supplement to the Official Journal of the European Union. The procedure designation "Open Procedure" used in the context of this announcement text in accordance with Section IV.1.1) and the specification of the award criteria in accordance with Section II.2.5) are due to the requirements of the notice form and have no further meaning. This, as well as the use of the medium "TED", does not involve any submission to procurement regulations, the validity of which is not mandatory by law or award regulations.

It is possible to join this open house biological process at any time within the contract period.

A contract is concluded with all pharmaceutical companies that meet the requirements of Annex 4 to the contract (self-declaration for approval and for the company) and confirm this with their signature.

This announcement does not apply to the award of a public contract within the meaning of the Public Procurement Directive (2014/24 / EC) or the antitrust law. In the interest of the broadest possible information for interested pharmaceutical companies, this announcement is made in the supplement to the Official Journal of the European Union. The procedure designation "Open Procedure" used in the context of this announcement text in accordance with Section IV.1.1) and the specification of the award criteria in accordance with Section II.2.5) are due to the requirements of the notice form and have no further meaning. This, as well as the use of the medium "TED", does not involve any submission to procurement regulations, the validity of which is not mandatory by law or award regulations.